Recent medical research breakthroughs have generated an unprecedented opportunity for potential new therapies—from genetic modifications to novel proteins—to address unmet needs in many medical areas like blindness and paralysis. At the March 19 WHIPgroup Meetup, Erika Smith of New Haven-based ReNetX Bio, will explore the science behind this new generation of biotech advancements and the opportunities for patients, researchers and investors.
Erika Smith is CEO of ReNetX Bio, a biotech firm that has created first in class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke and glaucoma. Ms. Smith has spent her career advancing entrepreneurs and investing in tech and biotech innovation. She was previously the Director for the $25 Million USD Blavatnik Fund for Innovation at Yale and was part of the leadership team at Yale Entrepreneurial Institute.
By: Jasmine B. Gratton, Matthew U. Silfin The U.S. Copyright Office has recently started reviewing claims at the new Copyright Claims Board (CCB). After some delay, the first claim was filed on June 16, 2022, [Read More…]
By Matthew U. Silfin, Jasmine B. Gratton Intellectual property is one of the most valuable assets a business can have, and those assets need to be protected. For many, quickly gaining intellectual property protection grants [Read More…]
By: Jasmine B. Gratton, Meghan E. McDermott The United States Patent and Trademark Office’s (USPTO) efforts to modernize its practices and increase the efficiency of examination have started to take shape. As of [Read More…]